LINC01117: A Long Intergenic Non-Protein Coding RNA (G102724224)

Target Name: LINC01117

NCBI ID: G102724224

LINC01117

Other Name(s): long intergenic non-protein coding RNA 1117 | Long intergenic non-protein coding RNA 1117

LINC01117: A Long Intergenic Non-Protein Coding RNA

LINC01117 is a long non-coding RNA (lncRNA) that has been identified in various studies as having important functional roles in various organisms, including humans. This RNA has been shown to play a key role in regulating gene expression, DNA replication, and other important cellular processes. As a result, LINC01117 has potential as a drug target or biomarker.

Diseased Implications

LINC01117 has been associated with a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that LINC01117 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that LINC01117 may be a promising target for cancer therapies.

In addition, LINC01117 has also been linked to a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Studies have shown that LINC01117 is expressed in the brains of individuals with these conditions, and that it is involved in the development and progression of these diseases. This suggests that LINC01117 may be a valuable biomarker for these conditions.

Role in Cellular Processes

LINC01117 is involved in a number of cellular processes that are important for proper cell function and survival. For example, LINC01117 has been shown to play a role in regulating gene expression and DNA replication in various cell types. This RNA has been shown to interact with DNA and to regulate the expression of other genes.

In addition, LINC01117 has also been shown to play a role in cellular signaling pathways. For example, studies have shown that LINC01117 can interact with the protein p53 and to regulate the expression of genes that are involved in the DNA damage response. This suggests that LINC01117 may be involved in cellular processes that are important for stress response and survival.

Potential Therapeutic Applications

The potential therapeutic applications for LINC01117 are vast and varied. As a drug target, LINC01117 may be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and developmental disorders. For example, LINC01117 has been shown to interact with various proteins and to regulate the expression of genes that are involved in cell signaling pathways. This suggests that it may be a useful target for therapies that target these pathways.

In addition, LINC01117 may also be used as a biomarker for a variety of diseases. For example, studies have shown that LINC01117 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that LINC01117 may be a valuable biomarker for these conditions.

Conclusion

LINC01117 is a long non-coding RNA that has been associated with a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its functional roles in cellular processes suggest that it may be a promising drug target or biomarker. Further research is needed to fully understand the potential therapeutic applications of LINC01117.

Protein Name: Long Intergenic Non-protein Coding RNA 1117

The "LINC01117 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01117 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets